Adult Dosing
- Adult Dosing is not applicable
Pediatric Dosing
Immunization against H influenzae type b and/or diphtheria, tetanus and pertussis (ActHIB)
Age 2-6 months at start of schedule
- 0.5 mL IM q8 wks x 3, followed by 0.5 mL IM booster x 1 at 15-18 months
Age 7-11 months at start of schedule
- 0.5 mL IM q8 wks x 2, followed by 0.5 mL IM booster x 1 at 15-18 months
Age 12-14 months at start of schedule
- 0.5 mL IM x 1, followed by 0.5 mL IM booster x 1 in 2 months
Note:Preterm infants should be immunized based on their chronological age from birth
Booster immunization against H influenzae type b (Hiberix)
Age 15 months to 4 years
Note:Hiberix is not indicated for primary immunization
[Outline]
See Supplemental Patient Information
- For intramuscular use only. Ensure that vaccine is not injected into a blood vessel
- In case of occurrence of Guillain-Barré syndrome within 6 weeks of prior vaccination with tetanus toxoid, the decision adminsiter any tetanus toxoid-containing vaccine should be taken after weighing potential benefits and risks
- The prefilled syringe tip caps of Hiberix contains natural rubber latex, and the vial stopper of ActHIB contains dry natural rubber latex which may result in allergic reactions in latex-sensitive individuals
- Syncope, sometimes accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements may occur following vaccination. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Prior to injecting vaccine, determine the patient's current health status and vaccination history for possible vaccine hypersensitivity
- Adequate treatment provisions, including epinephrine, should be available for immediate use should an acute anaphylactic reaction or other allergic reactions occur
- Safety and efficacy in immunosuppressed patients have not been assessed. The expected immune response may not be observed in patients receiving immunosuppressive therapy
- Vaccination is not contraindicated in minor illnesses such as upper respiratory infection with or without low-grade fever
- Urine antigen detection may not give a diagnostic in suspected disease due to H. influenzae type b within 1 to 2 weeks vaccination
- Cases of H. influenzae type b disease have been reported following vaccination and prior to the onset of protective effects of the vaccine
- This vaccine is not a substitute for routine tetanus immunization
Cautions: Use cautiously in
- Latex-sensitive patients
- Guillain-Barré syndrome within 6 wks of prior tetanus vaccine
- Immunocompromised patients
- Acute illness
Supplemental Patient Information
- Inform the patient, parent or guardian about the benefits and risks associated with vaccination
Pregnancy Category:C
Breastfeeding: As per the CDC and several health professional organizations, vaccines given to a nursing mother do not affect the safety of breastfeeding for mothers or infants. Nursing is not a contraindication to vaccination with haemophilus vaccines. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 23 December 2013). Safety unknown as per manufacturer.
